English

Elos Medtech Interim Report 1 January – 30 September, 2023

Report this content

July – September 2023

  • Net sales for the third quarter amounted to SEK 251.2 (231.5) million, an increase of 8.5 percent compared to the same quarter last year. Net sales in local currencies increased by 4.3 percent.
  • Operating profit amounted to SEK 31.7 (37.7) million, corresponding to an operating margin of 12.6 (16.3) percent.
  • Profit after net financial items amounted to SEK 30.9 (29.0) million. Net financial items were positively affected by exchange rate differences of SEK 7.5 (-5.3) million and totaled SEK -0.8 (-8.7) million.
  • Cash flow from operating activities was SEK 29.0 (55.3) million, and SEK -25.1 (25.6) million after investments.
  • Earnings per share amounted to SEK 2.68 (2.71).

For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342 , e-mail: stefano.alfonsi@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76 633 32 33, e-mail: ewa.linsater@elosmedtech.com

This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on October 19, 2023, at 08:00 (CEST). 

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags:

Interim report Medical Devices Elos Medtech

Subscribe

Documents & Links